Step 1 topics → Cardiovascular → Antiarrhythmics (Class I-IV + Others)

Antiarrhythmics (Class I-IV + Others)

USMLE Step 1 trap: Selects Class Ia over Class Ib for ischemic arrhythmias, missing Ib's selective affinity for inactivated channels in depolarized tissue. Class Ib agents (lidocaine, mexiletine) preferentially bind inactivated Na+ channels, which are more abundant in depolarized ischemic tissue, making Ib the class of choice post-MI.

Antiarrhythmics are one of the highest-yield pharmacology topics on USMLE Step 1, and they're also one of the most commonly botched. Students consistently blur Class Ib selectivity for ischemic tissue — they know lidocaine “blocks Na+ channels” but don't understand why it concentrates its effect in depolarized, inactivated-channel-rich ischemic tissue, which is exactly what makes it the right choice post-MI while Class Ia is wrong. The Vaughan Williams classification (Classes I–IV) gives you a framework, but the exam doesn't just ask you to match a drug to a class — it expects you to know why a drug behaves the way it does in specific clinical contexts. That means understanding channel kinetics, ECG changes, and organ-level toxicities well enough to apply them to a clinical vignette. If your mental model is just a table of drug-to-class matchings, you're going to struggle.

The trickiest areas cluster around three things: Class Ib selectivity for ischemic tissue (which requires understanding Na+ channel states, not just 'it blocks Na+ channels'), amiodarone's absurdly broad toxicity profile (most students only remember thyroid), and the CAST trial lesson about Class Ic agents post-MI. USMLE Step 1 loves to test whether you can apply the Ib/ischemic tissue relationship — not just recall it — and will often dress it up as a post-MI arrhythmia management question where you have to pick between Class Ia and Ib. Getting that wrong usually means you've missed the inactivated-channel concept entirely.

Adenosine and digoxin round out the high-yield content. Both affect the AV node, both appear in PSVT or rate-control vignettes, and both have specific mechanisms the exam expects you to know cold. Verapamil is another frequent trap — students know it's a calcium channel blocker but blank on what that means for the ECG. Build your understanding mechanistically and these clicks into place quickly.

From real student decks
97%have cards covering this topic
76%have mature cards
3.0median lapses in 14 days

One of the more frequently lapsed topics in Cardiovascular — most students have the cards but struggle to retain them.

Common misconceptions

Common mistake
Wrong: Class Ia agents are preferred in ischemic tissue because they block Na+ channels broadly.
Right: Class Ib agents (lidocaine, mexiletine) preferentially bind inactivated Na+ channels, which are more abundant in depolarized ischemic tissue, making Ib the class of choice post-MI.
Class Ia agents block Na+ channels but without selectivity for channel state — they work on resting and inactivated channels roughly equally. Class Ib agents (lidocaine, mexiletine) have a much higher affinity for the inactivated state of the Na+ channel. In ischemic tissue, where cells are persistently depolarized, more channels are stuck in the inactivated state, so Ib agents concentrate their effect exactly where the problem is. This is why Ib is the class of choice for ischemic and post-MI ventricular arrhythmias, not Ia.
Common mistake
Wrong: Ischemic depolarization decreases the proportion of Na+ channels in the inactivated state.
Right: Ischemic depolarization holds the membrane at a less negative potential, trapping more Na+ channels in the inactivated state and increasing the inactivated-channel population.
Na+ channels cycle through resting, open, and inactivated states. Ischemia depolarizes the membrane (makes it less negative), and a depolarized membrane cannot allow Na+ channels to fully repolarize back to the resting state — they get stuck in the inactivated state. So ischemia actually increases the proportion of channels in the inactivated state. This is the opposite of what many students assume, and it's exactly why Class Ib drugs become more effective (not less) in ischemic tissue.
Common mistake
Wrong: Students are unsure whether verapamil affects the PR interval.
Right: Verapamil (Class IV, L-type Ca2+ channel blocker) slows AV nodal conduction, prolonging the PR interval on ECG.
AV nodal conduction depends on L-type Ca2+ channels, not Na+ channels. Verapamil blocks L-type Ca2+ channels, slowing the rate of conduction through the AV node. On the ECG, slower AV nodal conduction manifests as a prolonged PR interval. This is the same mechanism that makes verapamil useful for rate control in atrial flutter/fibrillation, and it's also why you avoid it with beta-blockers — additive AV block risk.
Common mistake
Wrong: Amiodarone causes pulmonary toxicity via beta-blockade of bronchial smooth muscle.
Right: Amiodarone causes pulmonary fibrosis via phospholipase inhibition leading to phospholipid accumulation in alveolar macrophages, not via beta-blockade.
Amiodarone's pulmonary toxicity is not a bronchospasm story — it's a phospholipid storage disease at the cellular level. Amiodarone inhibits phospholipases, causing phospholipid accumulation inside alveolar macrophages, ultimately leading to inflammation and fibrosis. This is a direct drug toxicity mechanism, not a beta-receptor phenomenon. Beta-blockade-related bronchoconstriction is a separate concern with different drugs and different pathophysiology.
Common mistake
Gap: Incomplete recall of the full organ toxicity profile of amiodarone beyond thyroid dysfunction
Amiodarone's major organ toxicities span thyroid (hypo- and hyperthyroidism), lung (pulmonary fibrosis), liver (hepatotoxicity), eyes (corneal microdeposits, optic neuropathy), and skin (blue-gray discoloration, photosensitivity).
Amiodarone's toxicity profile is broader than most students memorize. The full list for Step 1 purposes: thyroid (both hypothyroid and hyperthyroid because it contains iodine and inhibits T4 conversion), lungs (pulmonary fibrosis via phospholipid accumulation), liver (elevated LFTs, hepatotoxicity), eyes (corneal microdeposits that are actually common and usually benign, plus optic neuropathy that is rare but serious), and skin (blue-gray discoloration from lipid accumulation in dermis, and photosensitivity). Nail all five organ systems — the exam can test any of them.
Common mistake
Wrong: Class Ic agents are safe to use for arrhythmia suppression after myocardial infarction.
Right: The CAST trial showed Class Ic agents (flecainide, encainide) increase mortality post-MI despite suppressing arrhythmias, so they are contraindicated in structural heart disease.
The CAST trial is one of the most tested clinical trial results on USMLE Step 1. The study enrolled post-MI patients with asymptomatic ventricular arrhythmias and showed that Class Ic agents (flecainide, encainide) suppressed the arrhythmias but increased overall mortality. The mechanism is thought to be pro-arrhythmic effects in the setting of structural heart disease. The take-home: arrhythmia suppression does not equal survival benefit, and Class Ic agents are contraindicated post-MI and in structural heart disease.
Common mistake
Wrong: Beta-blockers can be used safely in patients with reactive airway disease because their cardiac efficacy outweighs the risk.
Right: Non-selective beta-blockers are contraindicated in reactive airway disease because β2 blockade causes bronchoconstriction; cardioselective agents carry relative risk and should be avoided when possible.
Non-selective beta-blockers block β2 receptors in bronchial smooth muscle, causing bronchoconstriction — this is a real, dangerous interaction in patients with asthma or COPD with reversible airway disease. Even 'cardioselective' agents (metoprolol, atenolol) lose their selectivity at higher doses and carry relative risk. The cardiac benefit does not override the bronchospasm risk in reactive airway disease patients, and the exam will specifically test whether you recognize this contraindication.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the four Vaughan Williams classes by their channel target, their ECG effect (which interval changes), and a prototype drug for each — the exam will give you a drug and ask what happens to the QRS, PR, or QT.
  2. Understand amiodarone as a multi-class drug with Class I, II, III, and IV properties, and know its full organ toxicity profile including thyroid (hypo and hyper), lung (pulmonary fibrosis via phospholipid accumulation), liver, eyes (corneal microdeposits, optic neuropathy), and skin (blue-gray discoloration, photosensitivity).
  3. Know how adenosine and digoxin each slow AV nodal conduction (adenosine via A1 receptor hyperpolarization; digoxin via vagotonic effect) and what clinical arrhythmias they treat, including their contraindications and reversal strategies.
  4. Apply the CAST trial finding: Class Ic agents (flecainide, encainide) are contraindicated in patients with structural heart disease or post-MI because they increase mortality despite suppressing arrhythmias — the exam will present a scenario where using them seems logical but is actually wrong.

Can you avoid these mistakes?

A 58-year-old man with a recent anterior STEMI develops sustained ventricular tachycardia in the ICU. Which class of antiarrhythmic is most appropriate, and what property of its mechanism makes it preferred in this post-ischemic setting?
A patient on amiodarone for 2 years presents with exertional dyspnea and a new interstitial infiltrate on chest X-ray. What is the cellular mechanism behind this complication, and what other organ toxicities should you be monitoring for in this patient?
You are managing a patient with new-onset atrial fibrillation and asymptomatic LV dysfunction after a myocardial infarction 6 months ago. A colleague suggests flecainide for rhythm control. What clinical trial evidence makes this plan dangerous, and what would be a safer alternative?
A patient with PSVT is given IV adenosine with no response, so verapamil is considered. What ECG interval does verapamil prolong, what is the underlying mechanism, and why would you avoid combining verapamil with a beta-blocker for rate control?

Related topics

ECG Basics Heart Development and Looping Cardiac Septation Fetal Circulation and Transition Coronary Arteries and Territories

See how your Anki deck covers this topic.

Upload your deck for a free audit →